• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

EPAD exhibits at AAIC

2019-07-29News

Members of the EPAD team attended the Alzheimer’s Association International Conference (AAIC) held on 14-18 July. They travelled to Los Angeles (US) from across Europe for the biggest event in dementia research.

The event featured a number of key symposia, focused topic sessions and poster presentations and highlighted significant progress, results and theories that will help bring the world closer to breakthroughs in dementia science.  The five-day scientific conference brought together nearly 6,000 leaders in dementia research including academics, clinical researchers, clinicians, investigators and the care research community.

This is the second year that we exhibited the EPAD studies with our EPAD branded green and white booth in the exhibition area. We are delighted that more than 350 people stopped by at the EPAD booth to learn more about the project and discuss further topics such as the EPAD data access process, the Longitudinal Cohort Study (LCS) set up and, of course, the Proof of Concept (PoC) study. It was also a great opportunity to meet many current and future EPAD collaborators.  

“It was as a real pleasure to attend AAIC in Los Angeles. It was my first AAIC and I really enjoyed the whole experience. Our booth was popular and it was great to be able to chat with so many attendees about the work we do in EPAD and establish new connections.” – Natalia Reglinska-Matveyev

EPAD also had a business suite at the exhibition area where many engaging meetings with potential interventional owners and other world experts on Alzheimer’s disease prevention took place. Altogether, the conversations we had at the booth and the business suite generated a rich exchange of ideas and we are excited that various collaborations are being considered.

“It was great to return to AAIC 2019 after the success of last year’s booth. This year we had even more visitors to the EPAD booth, with increases in both industry and academics. Many of the people I spoke with came to the booth as they had heard about the work EPAD was doing and wanted to find out more about how they could get involved. Hot topics once again included data access, and I’m looking forward to seeing what questions the EPAD data is going to be able to help the scientific community answer.” – Sarah Gregory

At AAIC 2019, the aim of the EPAD booth was twofold. Our first aim was to showcase the EPAD PoC trial platform and engage the pharma and biotech industry. To support this a new high quality animated video was created to highlight the key benefits of the EPAD approach to develop drugs for Alzheimer’s disease (you can watch it here). Our second aim was to show all the benefits that EPAD has to offer to the scientific community. In order to do so, the EPAD booth included an interactive screen on which attendees could browse their topics of interest including the LCS and PoC studies, the EPAD Academy, the data access process and upcoming data batches, disease modelling, the statistical study design and interviews and testimonials of many EPADistas and collaborators.

“AAIC was a fantastic opportunity to show to the AD world what EPAD has done in the last 4,5 years. After reading the name of the project, many people came to the booth asking what we had in mind to prevent Alzheimer´s dementia. Their reaction was often a “Wow”. – Laura Carrera Carballés. 

Additionally, we are glad that the EPAD team had two oral presentations at AAIC on different aspects of the project. Both generated a great deal of interest from researchers outside the project: 

  • “Associations between Multimorbidity and CSF Amyloid: Cross-Sectional Analysis of the European Prevention of Alzheimer’s Dementia (EPAD) Cohort” from Lucy Stirland (UEDIN)
  • “Prescreening for European Prevention of Alzheimer Dementia (EPAD) Trial-Ready Cohort: Impact of AD risk factors and recruitment settings” from Lisa Vermunt (VUmc).

AAIC enabled the EPAD team to network and catch up with a lot of our colleagues and AAIC attendees. We would like to thank all the EPAD members who made this possible. We are very proud of the dedicated people working in our consortium spanning public and private sector organisations across Europe.

“Introducing EPAD to new people was very enjoyable; they are astonished by our vast network of sites and the sheer volume of data & samples we collect under the LCS. Many people specifically came to the EPAD booth to ask how they could access our data. We are looking forward to November to see how many data access request we receive once version V500.0 is released to external researchers. Everyday Craig and Kristy had positive meetings with potential, known and new Intervention Owners. The EPAD booth, our networking at the Universal Studio’s and throughout the conference was a real team effort which I have no doubt will bare autumn fruits.” – Emilie Delpon

 

Pictured: The EPAD team at the AAIC booth – From left to right, Craig Ritchie (UEDIN), Kristy Draper (UEDIN), Laura Carrera Carballés (Janssen), Kathryn Carruthers (UEDIN), Natalia Reglinska-Matveyev (UEDIN),  Sarah Gregory (UEDIN) and Emilie Delpon (UEDIN).

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT